NCT03025009View on ClinicalTrials.gov

A Study of LY3192767 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

April 11, 2018

Study Completion Date

April 11, 2018

Conditions
Healthy
Interventions
DRUG

LY3192767

Administered SC.

DRUG

Basal Insulin Peglispro

Administered SC.

DRUG

Insulin Glargine

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

41460

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03025009 - A Study of LY3192767 in Healthy Participants | Biotech Hunter | Biotech Hunter